Cancer care during COVID-19, part 2: thousands of diagnoses likely to be missed or delayed

  • Murray A; Kleinrock M.
  • IQVIA Institute for Human Data Science
  • 29 Apr 2020

  • curated by Pavankumar Kamat
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • According to a report by the IQVIA Institute for Human Data Science, more than 80,000 diagnoses of 5 common cancers in the United States may be missed or delayed by early June 2020 as a result of COVID-19-related health care disruptions.

Why this matters

  • The COVID-19 pandemic has affected the entire US health care system, including cancer care, directly and indirectly.

Study design

  • Analysis of data from IQVIA’s medical claims database, which includes >205 million patients, >1.7 billion claims, and 3 billion service records obtained annually.
  • Funding: No external funding from industry or government.

Key results

  • Rates of screening and monitoring for breast, prostate, colorectal, cervical, and lung cancer had declined by 39%-90% in early April compared with February (baseline month).
  • At current positivity rates, estimates for missed or delayed cancer diagnoses from early March through early June are as follows:
    • Breast: 36,000;
    • Lung: 450;
    • Cervical: 2500;
    • Colorectal: 18,800; and
    • Prostate: 22,600.
  • 22 million tests for the 5 cancers are expected to be canceled or delayed during the 3-month period.

Limitations

  • Claims data often have limited clinical information.